Arnaud Françoise, Hammett Michael, Philbin Nora, Scultetus Anke, McCarron Richard, Freilich Daniel
Combat Casualty Care, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
Blood Coagul Fibrinolysis. 2008 Oct;19(7):669-77. doi: 10.1097/MBC.0b013e3283089198.
The combination of traumatic injury, hemorrhage, and fluid resuscitation results in consumption and dilution of coagulation factors, adversely impacting hematology outcome in trauma patients. The hemostatic effects of escalating doses of recombinant factor VIIa added to hemoglobin-based oxygen carrier-201 were assessed as prehospital fluid resuscitation in swine with severe uncontrolled hemorrhage. Swine underwent liver injury causing severe uncontrolled hemorrhage and shock. During a 4-h prehospital phase, either hypotensive or tachycardic, or both, animals were resuscitated with hemoglobin-based oxygen carrier-201 without (0x) or with escalating doses of recombinant factor VIIa [90 microg/kg (1x), 180 microg/kg (2x), or 360 microg/kg (4x)]. The animals received one initial full dose of 10 ml/kg at 15 min and up to four doses of 5 ml/kg thereafter. From 4 to 72 h (hospital phase), animals received either transfusions or isotonic saline or both as needed. Hematology profile (complete blood count), thromboelastography, in-vitro bleeding (platelet function analyzer), and coagulation (prothrombin time) were measured and the results were compared using mixed statistical models. In all groups, dilutional coagulopathy was evidenced by reduced hematocrit, platelets, and thromboelastography-maximum amplitude, and increased platelet function analyzer closure time and thromboelastography-reaction time. During the prehospital phase, hemoglobin-based oxygen carrier-201 restored hemoglobin in all groups. Recombinant factor VIIa decreased prothrombin time in recombinant factor VIIa groups compared with the hemoglobin-based oxygen carrier-201 group (P < 0.01). Unexpectedly, increasing recombinant factor VIIa dosage tended to increase fluid requirement (P > 0.05). Compared with hemoglobin-based oxygen carrier, 1x recombinant factor VIIa tended to decrease blood loss, lactate and thromboelastography-reaction time at 24 h but the 4x group increased these parameters. Platelets and thromboelastography-maximum amplitude decreased (P < 0.01) with the 4x group. In swine with severe uncontrolled hemorrhage, prehospital resuscitation with escalating doses of recombinant factor VIIa in combination with hemoglobin-based oxygen carrier-201 did not change survival or hemostasis. However, there were trends toward possible benefits of low recombinant factor VIIa doses, whereas high recombinant factor VIIa doses adversely affected hemostasis.
创伤性损伤、出血和液体复苏共同作用,会导致凝血因子的消耗和稀释,对创伤患者的血液学转归产生不利影响。在严重无法控制出血的猪中,评估了在基于血红蛋白的氧载体-201中添加递增剂量重组因子VIIa作为院前液体复苏的止血效果。猪接受肝损伤以造成严重无法控制的出血和休克。在4小时的院前阶段,动物出现低血压或心动过速,或两者皆有,分别用基于血红蛋白的氧载体-201(未添加重组因子VIIa,即0倍剂量组)或递增剂量的重组因子VIIa[90微克/千克(1倍剂量组)、180微克/千克(2倍剂量组)或360微克/千克(4倍剂量组)]进行复苏。动物在15分钟时首先接受10毫升/千克的初始全剂量,此后最多接受4次5毫升/千克的剂量。在4至72小时(院内阶段)内,根据需要给动物输血、输注等渗盐水或两者皆输。检测血液学指标(全血细胞计数)、血栓弹力图、体外出血(血小板功能分析仪)和凝血指标(凝血酶原时间),并使用混合统计模型比较结果。在所有组中,稀释性凝血病表现为血细胞比容、血小板和血栓弹力图最大振幅降低,血小板功能分析仪封闭时间和血栓弹力图反应时间延长。在院前阶段,基于血红蛋白的氧载体-201使所有组的血红蛋白得以恢复。与基于血红蛋白的氧载体-201组相比,重组因子VIIa组的凝血酶原时间缩短(P<0.01)。出乎意料的是,重组因子VIIa剂量增加往往会使液体需求量增加(P>0.05)。与基于血红蛋白的氧载体相比,1倍剂量的重组因子VIIa在24小时时倾向于减少失血量、乳酸水平和血栓弹力图反应时间,但4倍剂量组却使这些参数增加。4倍剂量组的血小板和血栓弹力图最大振幅降低(P<0.01)。在严重无法控制出血的猪中,院前给予递增剂量的重组因子VIIa联合基于血红蛋白的氧载体-201进行复苏,并未改变生存率或止血情况。然而,低剂量重组因子VIIa有产生潜在益处的趋势,而高剂量重组因子VIIa对止血有不利影响。